- Home
- HPI vs AUTL Comparison
HPI vs AUTL Comparison
Compare HPI & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPI
- AUTL
- Stock Information
- Founded
- HPI 2002
- AUTL 2014
- Country
- HPI United States
- AUTL United Kingdom
- Employees
- HPI N/A
- AUTL N/A
- Industry
- HPI Trusts Except Educational Religious and Charitable
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HPI Finance
- AUTL Health Care
- Exchange
- HPI Nasdaq
- AUTL Nasdaq
- Market Cap
- HPI 431.9M
- AUTL 359.3M
- IPO Year
- HPI N/A
- AUTL 2018
- Fundamental
- Price
- HPI $15.77
- AUTL $1.75
- Analyst Decision
- HPI
- AUTL Strong Buy
- Analyst Count
- HPI 0
- AUTL 5
- Target Price
- HPI N/A
- AUTL $9.32
- AVG Volume (30 Days)
- HPI 64.7K
- AUTL 2.4M
- Earning Date
- HPI 01-01-0001
- AUTL 05-08-2025
- Dividend Yield
- HPI 8.97%
- AUTL N/A
- EPS Growth
- HPI N/A
- AUTL N/A
- EPS
- HPI N/A
- AUTL N/A
- Revenue
- HPI N/A
- AUTL $9,011,000.00
- Revenue This Year
- HPI N/A
- AUTL $329.53
- Revenue Next Year
- HPI N/A
- AUTL $191.73
- P/E Ratio
- HPI N/A
- AUTL N/A
- Revenue Growth
- HPI N/A
- AUTL N/A
- 52 Week Low
- HPI $12.85
- AUTL $1.11
- 52 Week High
- HPI $16.83
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- HPI 42.77
- AUTL 66.44
- Support Level
- HPI $15.77
- AUTL $1.19
- Resistance Level
- HPI $15.98
- AUTL $1.79
- Average True Range (ATR)
- HPI 0.19
- AUTL 0.11
- MACD
- HPI -0.04
- AUTL 0.05
- Stochastic Oscillator
- HPI 10.17
- AUTL 93.39
About HPI John Hancock Preferred Income Fund of Beneficial Interest
John Hancock Preferred Income Fund is a closed-end, diversified management investment company. Its primary investment objective is to provide a high level of current income consistent with preservation of capital. The fund's secondary investment objective is to provide growth of capital to the extent consistent with its primary investment objective. It seeks to achieve its investment objectives by investing in securities that may be undervalued relative to similar securities in the marketplace. The fund's principal investment strategies include investing a majority of its assets in preferred stocks and other preferred securities. Its portfolio composition consists of U.S preferred securities, common stocks, foreign preferred securities, corporate bonds, and short-term investments.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.